Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
207 - If only US data is available for a particular disease, is that acceptable by PAAB?
-
In the absence of Canadian data for disease prevalence, PAAB will consider U.S. data providing it is a reasonable representation of the Canadian environment. An example where geography may differ significantly is microbial prevalence and susceptibility. PAAB will base its review of the data on the specific disease state. When deemed appropriate, the data should be based on recent authoritative consensus guidelines, recognized medical texts or primary epidemiology studies. The presentation of the data should clearly indicate the geographic location and date the data was obtained.
